Pancreatic Neuroendocrine Tumors Clinical Trial
Official title:
A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors
Verified date | June 2014 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of the study is to evaluate the effect of Sunitinib on the clinical benefit response rate.
Status | Completed |
Enrollment | 12 |
Est. completion date | November 2013 |
Est. primary completion date | July 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have advanced (unresectable or metastatic) biopsy-proven pancreatic NET (Neuroendocrine Tumor) Exclusion Criteria: - Patients with poorly differentiated neuroendocrine cancer are not eligible |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Japan | National Cancer Center Hospital | Chuo-ku | Tokyo |
Japan | Kyushu University Hospital | Fukuoka | |
Japan | Aichi Cancer Center Central Hospital | Nagoya | Aichi |
Japan | Osaka Police Hospital | Osaka |
Lead Sponsor | Collaborator |
---|---|
Pfizer |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Benefit Response Rate (CBR) | CBR rate is defined as the percentage of participants with a best overall response of confirmed complete response (CR), confirmed partial response (PR) ,or stable disease (SD) = 24 weeks. Based on RECIST, CR is defined as the disappearance of all target lesions and PR is defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesion. SD is defined neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest dimensions since the treatment started. |
Up to 799 days of treatment | No |
Secondary | Objective Response Rate (ORR) | ORR is defined as the percentage of participants with a best overall response of confirmed CR or confirmed PR. Based on the response evaluation criteria in solid tumors (RECIST), CR is defined as the disappearance of all target lesions and PR is defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesion. | Up to 799 days of treatment | No |
Secondary | Tumor Shrinkage | Tumor shrinkage is defined as the percent change from baseline for the sum of the longest diameter of target lesions in participants. | Up to 799 days of treatment | No |
Secondary | Progression-free Survival (PFS) | PFS is defined as the time from registration to first documentation of progressive disease (PD) or to death due to any cause, whichever occurs first. | Up to 799 days of treatment | No |
Secondary | Overall Survival (OS) | Overall Survival (OS) is defined as the time from registration to documentation of death due to any cause. | Up to 3 years from the last subject registration to the study | No |
Secondary | Dose-corrected Trough Plasma Concentrations of Sunitinib, SU012662 and Total Drug (Sunitinib + SU012662). | Reference dose is 37.5 mg. Dose-corrected concentration is calculated from the following formula, "observed concentration multiplied by 37.5" over "actual dose". SU012662 is an active metabolite of sunitinib. |
Predose of Cycle 1 Day15, Cycle 2 Day1, Cycle 3 Day1, and Cycle 4 Day 1 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03053999 -
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
|
||
Completed |
NCT02586844 -
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
|
||
Terminated |
NCT00947167 -
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
|
Phase 2 | |
Completed |
NCT02842749 -
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
|
Phase 4 | |
Unknown status |
NCT01381822 -
Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
|
Phase 1 | |
Completed |
NCT01384617 -
Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy
|
N/A | |
Completed |
NCT02841865 -
Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
|
||
Completed |
NCT02685553 -
Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project
|
Phase 1 | |
Completed |
NCT02282059 -
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
|
||
Terminated |
NCT01648465 -
Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors
|
Phase 2 | |
Terminated |
NCT02110563 -
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1 | |
Completed |
NCT02125929 -
Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms
|
N/A |